MAPK signaling are typically active in colorectal cancer and drive tumor progression. 6 Although targeting WNT appears to be difficult, 7 MAPK signaling can be inhibited by antibodies against EGFR or by MEK inhibitors that block signal transduction and thus may slow tumor progression. 8 Combining such treatment with chemotherapy may increase response rates even further, 9, 10 although, based on other data, the superiority of such combinations remains a matter of debate. 11 Nevertheless, current guidelines recommend adding anti-EGFR-directed therapy to FOLFOX or FOLFIRI protocols for colorectal cancers without activating RAS mutations. 2 Besides WNT and MAPK signaling, activation of NOTCH signaling has been observed in colorectal cancer. Although in treatment trials, NOTCH repression by γ-secretase inhibitors has so far been disappointing, 12, 13 we recently showed that dual inhibition of MAPK and NOTCH signaling by MEK and γ-secretase inhibitors strongly repressed colon cancer growth. 14 However, it remains to be determined whether combined MAPK and NOTCH repression may add benefit to established chemotherapeutic regimens. Furthermore, it is generally unknown to what extent chemotherapeutic treatments may impact on signaling pathway activities in colorectal cancer and thus modulate their targetability.
To address these problems, we herein gauged the impact of cytotoxic chemotherapy on WNT, MAPK and NOTCH activity in colorectal cancer in vivo. Furthermore, we assessed whether combining dual MAPK and NOTCH inhibition with chemotherapy may be a promising treatment strategy for more effective management of patients with colorectal cancer.
| MATERIAL S AND ME THODS

| Cell culture
We obtained SW1222 colon cancer cells from the Ludwig Institute for Cancer Research (New York, NY, USA) and SW480 colon cancer cells from ATCC. SW1222 has a deletion of 113 bp in exon 1 of TP53, causing loss of p53 protein expression, a truncating mutation in APC(E1306*), and an activating mutation in KRAS(A146V).
15,16
SW480 carries mutated p53(R273H/P309S), truncated APC(Q1338*), and also has an activating mutation in KRAS(G12V).
Both cell lines were derived from colorectal adenocarcinomas, are microsatellite stable and tumorigenic in NOD/SCID mice. 14 Cell line identity was verified by short-tandem repeat profiling, and both cell lines tested negative for Mycoplasma contamination. Cell lines were cultured in DMEM containing 10% FBS, 100 U/mL penicillin, and 0.1 mg/mL streptomycin (Biochrom, Berlin, Germany).
| Tumor xenografts and in vivo treatments
Mouse experiments were reviewed and authorized by the dis- 
| Chemotherapy and inhibitor treatment
Irinotecan was obtained from Pfizer (Berlin, Germany), selumetinib (AZD) from Selleck Chemicals (Munich, Germany), and dibenzazepine (DBZ) from Axon Medchem (Groningen, the Netherlands).
All other chemicals were obtained from Sigma (St Louis, MO, USA). 
| Statistical analyses and data availability
Sample sizes were based on preliminary data and previous experience. To analyze differences between groups, we used two-tailed Student's t test, and data are mean ± SD if not indicated otherwise.
The Kaplan-Meier method was used to show differences in tumor survival, for which tumor diameters of 1.5 cm were defined as end- 
| RE SULTS
| Limited effects of chemotherapy on signaling pathway activity in colon cancer
To determine the effects of chemotherapy on signaling pathway activity, we examined SW1222 and SW480 colon cancer xeno- showed that all xenografts had retained substantial amounts of vital tumor tissue ( Figure 1A) . Morphologically, irinotecan, either alone or in combination with 5-FU, showed the strongest cytopathic effects with swollen tumor cells, giant and irregular nuclei, and pale cytoplasm, whereas the other treatments did not cause overt morphological changes upon this short-term treatment ( Figure 1A ).
We then examined these xenograft tumors for nuclear β-catenin, which indicates WNT signaling activity. 18 Non-treated SW480 and SW1222 colon cancer xenografts showed accumulation of nuclear β-catenin in tumor cells that tended to be more pronounced at the tumor edge ( Figure 1B ). Interestingly, in SW480 xenografts, treatment with irinotecan or FOLRIFI caused a loss of nuclear β-catenin staining in some tumor cells, and this effect was significant after 
| Combining MAPK and NOTCH-targeted treatment with 5-FU chemotherapy
We previously showed that combined inhibition of MAPK and NOTCH signaling slowed tumor growth in colon cancer xenografts.
14 In order to compare these therapeutic effects with chemotherapy, we treated SW480 and SW1222 xenografts for longer terms of up to 31 days with 5-FU chemotherapy or, for MAPK and NOTCH inhibition, with AZD and DBZ ( Figure 3A ). Furthermore, we tested for additive effects of chemo-and inhibitor therapy. Non-treated xenografts served as controls. All treatment protocols significantly slowed growth of SW480 and SW1222 colon cancer xenografts ( Figure 3B ) and prolonged survival ( Figure S2 ). In SW480 tumors, therapy with 5-FU or with AZD and DBZ was similarly effective in reducing tumor growth. In SW1222, combined AZD and DBZ was slightly more effective than 5-FU monotherapy, but this difference was non-significant ( Figure 3B) . Unexpectedly, when we tested the combination of 5-FU treatment with AZD and DBZ, we found that this did not significantly improve therapy effects ( Figure 3B ).
However, in SW1222 xenografts, the combination nearly caused full arrest of tumor growth.
To further assess treatment effects, we analyzed xenografts that Taken together, these data showed that therapeutic effects of 5-FU or MAPK and NOTCH inhibition on tumor growth were similar. Combining both treatments did not significantly improve therapy response.
| Impact of 5-FU, MAPK and NOTCH inhibition on proliferation and apoptosis
To better understand the observed therapeutic effects on colon cancer xenografts, we analyzed proliferation and apoptosis rates in treated tumors. In SW480 colon cancer xenografts, 5-FU monotherapy slightly reduced proliferation as assessed by Ki-67 immunostaining when compared to non-treated control tumors ( Figure 4A,B) . AZD and DBZ treatment reduced Ki-67 proliferation rates more strongly in these tumors ( Figure 4A,B) . However, combining both treatments had only slightly more repressive effects on proliferation than AZD and DBZ alone. Similar, but overall, stronger repressive effects of these treatments were observed in SW1222 colon cancer xenografts, where AZD and DBZ in combination with 5-FU reduced the frequency of Ki-67-positive tumor cells by more than 50% ( Figure 4A,B) .
We then examined apoptosis by analyzing cleaved Caspase-3. In both SW480 and SW1222 xenografts, apoptosis rates increased upon treatment with 5-FU, AZD and DBZ, or their combination, when compared to non-treated controls ( Figure 4C,D) . This increase was more pronounced in SW1222 than in SW480-derived xenograft tumors.
However, the combination of 5-FU with AZD and DBZ did not significantly increase apoptosis when compared to either treatment alone ( Figure 4D ).
Taken together, these findings indicated that MAPK and NOTCH inhibition had stronger repressive effects on colon cancer proliferation than 5-FU monotherapy, whereas apoptosis rates were similarly affected by either treatment modality or their combination.
| Effects of 5-FU, MAPK and NOTCH inhibition on thymidylate synthase expression
Resistance to therapy with 5-FU may be caused by increased expression of thymidylate synthase. In order to examine whether this mechanism may be relevant for our observations, we analyzed thymidylate synthase expression in treated and non-treated xeno- In conclusion, we herein demonstrate that combining chemotherapy with therapeutic targeting of signaling pathways that are active in colon cancer may not generally result in additive therapeutic effects. We suggest this may, in part, be due to reduced proliferation upon pathway inhibition and thus decreased efficacy of cytotoxic agents. However, our study has certain limitations.
| D ISCUSS I ON
The data we show were derived from immune-compromised animals, which partially lack an inflammatory microenvironment and tumor-directed immune response. 17 Treatment effects in human patients with colorectal cancer may thus differ significantly. Moreover, the SW1222 and SW480 xenograft models we used showed a variable response of tumor cell subpopulations to cytotoxic treatments, despite a comparable genetic background with microsatellite stability and mutations in TP53, APC and KRAS genes. It therefore remains to be determined to what extent our findings depend on individual tumor characteristics, keeping in mind that colon cancers are genetically heterogeneous malignancies. 25, 26 Further study in this context may then inform therapeutic trials in order to determine treatment combinations that provide benefit for patients with colorectal cancer.
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